Medicine:mRNA-1283
From HandWiki
Short description: Vaccine candidate against COVID-19
| Vaccine description | |
|---|---|
| Target disease | SARS-CoV-2 |
| Type | mrna |
| Clinical data | |
| Trade names | Spikevax[1] |
| Routes of administration | Intramuscular |
mRNA-1283 is a COVID-19 vaccine candidate developed by Moderna.[2][3]
An expectation, or hope seems to be that this "next generation" vaccine can be stored at regular refrigerator temperature (2-5 °C). [citation needed]
Clinical Trial
In December, Moderna started a clinical trial which would evaluate the vaccine's ability to provoke an immune response and its safety. As of September 2022, the trial is in Phase 2 [4]
References
- ↑ "Moderna Announces Significant Advances Across Industry-Leading mRNA Portfolio at 2021 R&D Day". Bloomberg. 9 September 2021. https://www.bloomberg.com/press-releases/2021-09-09/moderna-announces-significant-advances-across-industry-leading-mrna-portfolio-at-2021-r-d-day.
- ↑ "A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19". ClinicalTrials.gov. 24 March 2021. NCT04813796. Retrieved 17 August 2021.
- ↑ "A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters". ClinicalTrials.gov. 30 November 2021. NCT05137236. Retrieved 30 November 2021.
- ↑ "A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters". https://clinicaltrials.gov/ct2/show/NCT05137236#studydesc.
 |
